FDA Approves Evolus' Novel Hyaluronic Acid Dermal Fillers with Superior Efficacy Profile
• Evolus, Inc. receives FDA approval for two new injectable hyaluronic acid dermal fillers, Evolysse Form and Evolysse Smooth, marking their entry into the dermal filler market.
• A pivotal clinical study of 140 patients demonstrated statistical superiority (P < .001) of both Evolysse products compared to Restylane-L in treating nasolabial folds.
• Both products showed comparable safety profiles to Restylane-L with only mild-to-moderate adverse events, and Evolysse Smooth achieved its results using 20% less product.
© Copyright 2025. All Rights Reserved by MedPath